Leerink Partnrs Weighs in on McKesson Co.’s Q3 2025 Earnings (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for shares of McKesson in a research report issued on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now expects that the company will earn $8.23 per share for the quarter, up from their previous forecast of $8.14. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s Q4 2025 earnings at $8.69 EPS.

A number of other research analysts also recently commented on the company. Morgan Stanley increased their price objective on McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a report on Monday, April 15th. UBS Group increased their price objective on McKesson from $575.00 to $620.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Barclays initiated coverage on McKesson in a report on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 price objective on the stock. Citigroup increased their price objective on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, Mizuho raised their price target on McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $533.50.

McKesson Stock Performance

MCK opened at $535.56 on Wednesday. McKesson has a one year low of $352.34 and a one year high of $543.00. The company has a market cap of $70.38 billion, a P/E ratio of 24.27, a PEG ratio of 1.43 and a beta of 0.45. The business’s 50-day simple moving average is $526.81 and its 200-day simple moving average is $488.48.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping the consensus estimate of $7.05 by $0.69. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company had revenue of $80.90 billion for the quarter, compared to the consensus estimate of $77.93 billion. During the same quarter in the prior year, the business earned $6.90 EPS. McKesson’s revenue was up 14.8% on a year-over-year basis.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.46%. McKesson’s dividend payout ratio (DPR) is presently 11.24%.

Insider Activity at McKesson

In related news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Brian S. Tyler sold 3,473 shares of the business’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the sale, the chief executive officer now owns 43,445 shares in the company, valued at $22,789,074.75. The disclosure for this sale can be found here. Company insiders own 0.21% of the company’s stock.

Institutional Trading of McKesson

A number of institutional investors have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its position in McKesson by 16.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock worth $2,238,953,000 after purchasing an additional 708,438 shares in the last quarter. Morgan Stanley raised its holdings in shares of McKesson by 14.0% in the third quarter. Morgan Stanley now owns 2,398,380 shares of the company’s stock worth $1,042,937,000 after acquiring an additional 294,832 shares during the last quarter. Norges Bank acquired a new position in shares of McKesson in the fourth quarter worth $1,024,140,000. Putnam Investments LLC raised its holdings in shares of McKesson by 3.2% in the fourth quarter. Putnam Investments LLC now owns 1,997,963 shares of the company’s stock worth $925,017,000 after acquiring an additional 62,242 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of McKesson by 3.3% in the third quarter. Northern Trust Corp now owns 1,595,162 shares of the company’s stock worth $693,656,000 after acquiring an additional 50,265 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.